TrialKey

Solutions

De-risk the trial before you commit.

TrialKey combines AI-enabled clinical research consulting, clinical development expertise, historical trial evidence, real-world data, regulatory precedent and commercial intelligence to make studies more recruitable, interpretable and likely to succeed.

Decisions supported

Portfolio and indication priority
Study design, feasibility and protocol quality
Country, site and recruitment strategy
Competitive intelligence and clinical operations risk

How TrialKey helps

Seven connected services across the development pathway.

Start with a clinical research consulting question, then draw on the strategy, study design, protocol-readiness, feasibility, country and site, competitive intelligence, clinical operations management or oversight capability needed to answer it.

Programme-wide decision support

1. Clinical Research Consulting and Development Strategy

Combine senior clinical-development expertise with TrialKey's AI, historical evidence and modelling to answer the programme's most important scientific, operational and investment questions.

  • Which asset, indication or development path is best supported?
  • What is the fastest credible path to proof-of-concept?
  • What synopsis, protocol, ethics and regulatory submission work is required?
  • What evidence and next actions should guide the programme decision?

Study design

2. Study Design and Protocol Optimisation

Generate evidence-grounded study designs from an indication and treatment, or optimise an existing draft protocol, using TrialKey's hybrid ML and agent workflow, expert input and programme constraints.

  • What alternative study designs should be considered?
  • How should eligibility criteria, endpoints and assessment timing change?
  • What sample size, visit schedule and duration are best supported?
  • Which expert-reviewed design should become the optimised study plan?

Protocol quality gate

3. Protocol Readiness Assessment

Grade clinical trial protocol readiness, identify the clinical trial factors that most matter, benchmark amendment and recruitment evidence, and prioritise improvements for human expert review.

  • Is the synopsis, study plan or protocol ready for its next decision point?
  • Which eligibility, endpoint, design or operational factors need attention?
  • What amendment and recruitment patterns provide useful historical context?
  • Which protocol changes should be prioritised for expert review?

Design validation

4. Clinical Trial Feasibility and Success Modelling

Evaluate a proposed clinical trial design against historical evidence, estimate its modelled probability of success, identify material risks and recommend better-supported alternatives before committing resources.

  • What is the starting design's modelled probability of success?
  • Which scientific, protocol and operational risks matter most?
  • Which variables are limiting feasibility or the chance of success?
  • What alternative design or expert-reviewed changes are recommended?

Recruitment and site strategy

5. Clinical Trial Recruitment and Site Strategy

Use AI to determine the required patient number and select the best continents, countries and sites, then support site negotiation, contracting, traditional site-led recruitment and digital patient recruitment through Trial Screen.

  • How many evaluable patients and total participants must be recruited?
  • Which continents, countries and sites offer the strongest recruitment opportunity?
  • How should site negotiation, contracting and activation be structured?
  • How should traditional and digital patient recruitment be combined and optimised?

Competitive strategy

6. Pharmaceutical Competitive Intelligence

Use AI to rank the closest competitor trials, model likely readouts and outcomes, compare mechanism and technology classes, and assess the clinical and commercial impact on the programme.

  • Who are the closest competitor trials and pipeline assets?
  • When are the most relevant competitors likely to report?
  • What is each competitor's modelled probability of success?
  • How could success, failure or delay affect our design and positioning?

Clinical operations management

7. AI-enabled Clinical Operations Intelligence and Study Oversight

Add a decision-intelligence layer across the sponsor's CTMS, CRO reports, site metrics and study data to monitor delivery, forecast outcomes and direct timely action.

  • How are CROs, countries and sites performing against the approved plan?
  • Where will recruitment, timelines, costs or enrolment outcomes finish at the current trajectory?
  • Which operational risks are emerging before they affect delivery?
  • What mitigation actions, owners and executive decisions are required?

Governance and execution

Clinical operations intelligence for the live trial.

TrialKey sits above the sponsor's CTMS, CRO reporting and study data to show whether the trial is still behaving like the plan that was approved, budgeted and optimised—and what to do when it is not.

CRO, country and site performance

Bring CRO reports, country metrics and site performance into one sponsor-side view of activation, enrolment, quality, milestones and delivery.

Recruitment tracking and forecasting

Track enrolment against plan by country and site, model the likely completion trajectory and identify where intervention can change the outcome.

Timeline and cost forecasting

Compare actual progress and spend with the approved assumptions, identify overrun drivers and reforecast key milestones and total trial cost.

Plan-versus-actual intelligence

Compare live study performance with the optimised study plan, surfacing material variance in recruitment, visits, data quality, endpoints and operations.

Emerging operational risk

Detect risks across recruitment, retention, CRO delivery, geography, budget, protocol compliance and data quality before they become missed milestones.

Mitigation and executive reporting

Recommend actions, assign accountable owners, track interventions and produce decision-ready dashboards for management, boards and investment committees.

Engagement pathways

Start with the decision you need to make.

Whether you need a fast read on a planned asset, a deeper trial-design optimisation programme, or sponsor-side execution oversight, TrialKey can meet the moment and expand as the programme progresses.

Pathway 1

Asset and Trial Diagnostic

Fast decision support and early budget planning before committing further capital, time, or operational resources.

  • Trial Probability Assessment
  • Protocol Strengths and Weaknesses
  • Early budget planning
  • Short executive memo

Pathway 2

Protocol Optimisation Programme

Improve trial design and quantify the expected impact on probability, cost, IP position, and delivery risk.

  • Probability Assessment Dashboard
  • Protocol Optimisation Simulation
  • Competitor Landscape
  • Patent and IP Landscape Report
  • Simulation-informed synopsis

Pathway 3

Execution Oversight

Give sponsors and partners an independent view of delivery, budget, data, and risk signals during the live trial.

  • Trial Management Dashboard
  • CRO and site performance monitoring
  • Cost and recruitment reforecasting
  • Monthly risk review

Next step

Bring us the decision you need to make.

Share the study, portfolio question, or live execution risk you want to evaluate. We will show how TrialKey would structure the evidence and what the first decision readout could look like.

Enquire now